Sherie Duncan

Dr. Sherie Duncan is the Vice President of Research Partnerships at AbCellera, a Canadian company that is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. Sherie works closely with AbCellera’s partners, which include leading pharmaceutical and biotech organizations, to advance programs to discover antibody-based medicines for a broad range of diseases from target to completion. Since joining AbCellera in 2015, Sherie has worked on more than 100 discovery programs, and AbCellera’s partners have advanced four of those programs to patients in clinical trials. Sherie contributed to the discovery and development of AbCellera’s two antibody treatments for COVID-19, bamlanivimab and bebtelovimab, which have treated an estimated 2.5 million patients, saving thousands of lives.

Sherie has over 15 years of management experience across biotechnology and scientific outreach and  is an expert in immunology, cell biology, and single cell assays. Her work is represented in dozens of peer-reviewed publications and abstracts, and she is the recipient of several awards from the Natural Sciences and Engineering Research Council of Canada (NSERC). Sherie has a PhD in Experimental Medicine from the University of British Columbia and a BSc in Biological Sciences from Simon Fraser University.